Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: A randomized trial

Menopause

Volumn 15, Issue 6, 2008, Pages 1132-1138

  Pelayo, Irene ^a,f   Haya, Javier ^b   De La Cruz, Juan J ^c   Seco, Carlos ^d   Bugella, Juan I ^d   Diaz, Jose L ^e   Bajo, Jose M ^b   Repolles, Manuel ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^f NONE   (Spain)

Author keywords

Bone loss prevention; Calcium carbonate; Ossein hydroxyapatite compound; Osteoporosis; Raloxifene; Ultrasound

Indexed keywords

CALCIUM CARBONATE; HYDROXYAPATITE; OSSEIN; RALOXIFENE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE DENSITY; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LEG SWELLING; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; OPEN STUDY; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ULTRASOUND; DRUG COMBINATION; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

BONE DENSITY CONSERVATION AGENTS; CALCIUM CARBONATE; DRUG THERAPY, COMBINATION; DURAPATITE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SATISFACTION; RALOXIFENE;

EID: 63349100554     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318170af33     Document Type: Article

References (40)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733.
2. Diaz Curiel M, Garcia JJ, Carrasco JL, et al. Prevalence of osteoporosis assessed by densitometry in the Spanish female population. Med Clin 2001;116:86-88.
3. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-367.
4. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-822.
5. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
6. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-1754.
7. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
8. Meunier PJ, Vignot E, Garnero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 1999;10:330-336.
9. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003;14:2-12.
10. Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2003;4:CD004526.
11. The North American Menopause Society. The role of calcium in peri- and postmenopausal women: consensus opinion of The North American Menopause Society. Menopause 2001;8:84-95.
12. Schmidt KH, Worner UM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 1988;11:107-115.
13. Stepan JJ, Pospichal J, Presl J, Pacovsk] V. Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women. Bone 1989;10:179-185.
14. Rüegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995;5:30-34.
15. Nilsen KH, Jayson MI, Dixon AS. Microcrystalline calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a controlled study. Br Med J 1978;2:1124.
16. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982;36:426-430.
17. Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin 1984;8:734-742.
18. Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J 1985;61:791-796.
19. Castelo-Branco C, Pons F, Vicente JJ, Sanjuán A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. J Reprod Med 1999;44:601-605.
20. Annefeld M, Caviezel R, Schacht E, Schicketanz KH. The influence of ossein-hydroxyapatite compound ('Ossopan') on the healing of a bone defect. Curr Med Res Opin 1986;10:241-250.
21. Castelo-Branco C, Martínez de Osaba MJ, Pons F, et al. Osseinhydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. J Reprod Med 1999;44:241-246.
22. Soballa T, Wüster C, Schlegel J, et al. Ultrasound transmission speed and ultrasound bone profile score (UBPS) of the phalanges in normal women and women with osteoporosis. Horm Metab Res 1998;30:536-541.
23. Mauloni M, Rovati LC, Cadossi R, de Terlizzi F, Ventura V, de Aloysio D. Monitoring bone effect of transdermal hormone replacement therapy by ultrasound investigation at the phalanx: a four-year follow-up study. Menopause 2000;7:402-412.
24. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-75.
25. Aguado F, Revilla M, Hernandez ER, Mellström B. Behavior of bone mass measurements. Dual energy x-ray absorptiometry total body bone mineral content, ultrasound bone velocity, and computed metacarpal radiogrammetry, with age, gonadal status, and weight in healthy women. Invest Radiol 1996;31:218-222.
26. Duboeuf F, Hans D, Schott AM, Giraud S, Delmas PD, Meunier PJ. Ultrasound velocity measured at the proximal phalanges: precision and age-related changes in normal females. Rev Rhum Engl Ed 1996;63:427-434.
27. Sili Scavalli A, Marini M, Spadaro A, Riccieri V, Cremona A, Zoppini A. Comparison of ultrasound transmission velocity with computed metacarpal radiogrammetry and dual-photon absorptiometry. Eur Radiol 1996;6:192-195.
28. Wüster C, Heilmann P, Pereira-Lima J, Schlegel J, Anstätt K, Soballa T. Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities. Exp Clin Endocrinol Diabetes 1998;106:277-288.
29. Kaufman JJ, Einhorn TA. Ultrasound assessment of bone. J Bone Miner Res 1993;8:517-525.
30. Gluer CC, Wu CY, Genant HK. Broadband ultrasound attenuation signals depend on trabecular orientation: an in vitro study. Osteoporos Int 1993;3:185-191.
31. Gluer CC, Wu CY, Jergas M, Goldstein SA, Genant HK. Three quantitative ultrasound parameters reflect bone structure. Calcif Tissue Int 1994;55:46-52.
32. Ventura V, Mauloni M, Mura M, Paltrinieri F, de Aloysio D. Ultrasound velocity changes at the proximal phalanxes of the hand in pre-, peri- and postmenopausal women. Osteoporos Int 1996;6:368-375.
33. de Aloysio D, Rovati LC, Cadossi R, et al. Bone effects of transdermal hormone replacement therapy in postmenopausal women as evaluated by means of ultrasound: an open one-year prospective study. Maturitas 1997;27:61-68.
34. Njeh CF, Boivin CM, Gough A, et al. Evaluation of finger ultrasound in the assessment of bone status with application of rheumatoid arthritis. Osteoporos Int 1999;9:82-90.
35. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003;32:83-113, vi-vii.
36. Prestwood KM, Pilbeam CC, Burleson JA, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994;79:366-371.
37. Midtby M, Magnus JH, Joakimsen RM. The Tromso Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int 2001;12:835-843.
38. Christiansen C, Riis BJ, Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int 1990;1:35-40.
39. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:543-547.
40. Nakaoka D, Sugimoto T, Kaji H, et al. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women. Osteoporos Int 2001;12:548-554.